PIK3CA and lung carcinoma: Despite the clear association between hyperactivation of the PI3K/Akt/mTOR pathway and poor prognosis in many tumor types, including lung cancer, the efficacy of mTOR inhibitors as monotherapy or in combinations with other targeted therapies is unsatisfactory.